Skip to main content
Equibles

GOLDMAN SACHS GROUP INC

Position in VRTX — Vertex Pharmaceuticals Inc / Ma

CIK 886982 NEW YORK, NY
Back to VRTX Full portfolio

Position in VRTX

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$1,232,765,138
+$153,087,240 QoQ
Shares Held
2,481,761
+2.6% QoQ
Ownership
0.979%
of shares outstanding
% of Portfolio
0.15%
of 13F equity value
Holder Rank
#22
of 1,732 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 90% Shared 0% None 10%

Common Shares in VRTX Over Time

Shares Held

Position Value (USD)

Derivatives in VRTX

reported options exposure · as of Jun 30, 2026
CallValue
$10,779,041
CallShares
21,700
PutValue
$14,156,805
PutShares
28,500

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

GOLDMAN SACHS GROUP INC holds $13,040,376,854 across 359 Biotechnology names. VRTX ranks #1 (9.5% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
This page 		2,481,761 $1,232,765,138
2 REGN
Regeneron Pharmaceuticals, Inc.
 1,163,191 $725,296,113
3 ROIV
Roivant Sciences Ltd.
 18,556,458 $656,713,046
4 TECH
BIO-TECHNE Corp
 7,343,324 $518,805,838
5 RVMD
Revolution Medicines, Inc.
 2,133,101 $399,487,154
6 MRNA
Moderna, Inc.
 4,671,950 $327,176,656
7 TNGX
Tango Therapeutics, Inc.
 9,980,620 $311,994,180
8 INCY
Incyte Corp
 2,305,782 $261,383,446

All Filings in VRTX

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $10,779,041 21,700
2026-06-30 $1,232,765,138 2,481,761
2026-06-30 $14,156,805 28,500
2026-03-31 $1,079,677,898 2,417,875
2026-03-31 $13,753,432 30,800
2026-03-31 $7,993,066 17,900
2025-12-31 $19,358,472 42,700
2025-12-31 $795,246,934 1,754,118
2025-12-31 $6,981,744 15,400
2025-09-30 $581,451,457 1,484,658
2025-09-30 $22,205,988 56,700
2025-09-30 $14,451,516 36,900
2025-06-30 $860,019,550 1,931,760
2025-06-30 $7,880,040 17,700
2025-06-30 $13,890,240 31,200
2025-03-31 $15,126,384 31,200
2025-03-31 $840,965,860 1,734,594
2025-03-31 $4,557,308 9,400
2024-12-31 $2,617,550 6,500
2024-12-31 $564,478,279 1,401,734
2024-12-31 $12,685,050 31,500
2024-09-30 $16,045,260 34,500
2024-09-30 $4,418,260 9,500
2024-09-30 $631,826,989 1,358,534
2024-06-30 $4,499,712 9,600
2024-06-30 $966,734,530 2,062,499
2024-06-30 $16,217,712 34,600
2024-03-31 $585,615,288 1,400,960
2024-03-31 $18,476,042 44,200
2024-03-31 $14,170,539 33,900
2023-12-31 $12,084,633 29,700
2023-12-31 $12,817,035 31,500
2023-12-31 $604,204,792 1,484,934
2023-09-30 $11,788,386 33,900
2023-09-30 $589,532,311 1,695,325
2023-09-30 $11,788,386 33,900
2023-06-30 $639,023,513 1,815,872
2023-06-30 $18,721,612 53,200
2023-06-30 $18,721,612 53,200
2023-03-31 $539,315,083 1,711,731
2023-03-31 $35,949,487 114,100
2023-03-31 $34,248,109 108,700
2022-12-31 $26,972,052 93,400
2022-12-31 $482,947,873 1,672,373
2022-12-31 $28,646,976 99,200
2022-09-30 $11,060,428 38,200
2022-09-30 $498,225,083 1,720,747
2022-09-30 $12,739,760 44,000
2022-06-30 $295,214,473 1,047,640
2022-03-31 $324,570,213 1,243,707

Report a Problem

Category
Description
Email (optional, for follow-up)